Enara Bio secures $32.5m for ‘Dark Antigen’ cancer therapies
Pfizer and Merck KGaA’s venture capital arms were among the backers in the Series B round.
Pfizer and Merck KGaA’s venture capital arms were among the backers in the Series B round.
What's Your Reaction?
